Then, we also experimentally validated RPN2 overexpression in clinical specimens with various grades and GBM cell lines, and there was a positive between RPN2 expression and WHO grade, which was consistent with bioinformatics analysis. This evidence concerns the gene RPN2 and glioblastoma.